-
- Topic
- Voices
- Last Post
-
-
New BRAF/MEK inhibitors coming to market
Started by:
in: Dosing and administration
- 1
- March 1, 2018 at 12:20 am
-
Adjuvant Immunotherapy in stage IIIA patients
Started by:
- 1
- March 1, 2018 at 12:16 am
-
Influenza and Tamiflu and Immunotherapy
Started by:
- 3
- February 25, 2018 at 10:12 pm
-
ASCO/NCCN guidlines now out
Started by:
- 4
- February 23, 2018 at 5:53 pm
-
hepatotoxicity
Started by:
- 5
- February 23, 2018 at 5:48 pm
-
Adjuvant Treatment with Targeted Therapy
Started by:
- 4
- February 23, 2018 at 5:43 pm
-
Adjuvant pembrolizumab
Started by:
- 4
- February 19, 2018 at 10:50 pm
-
Reimbursement for infliximab
Started by:
- 6
- February 17, 2018 at 11:10 pm
-
Family planning
Started by:
- 4
- February 16, 2018 at 4:44 pm
-
Infusion times
Started by:
- 8
- February 15, 2018 at 3:41 pm
-
Practice volume
Started by:
- 2
- February 15, 2018 at 3:37 pm
-
TVEC infection control practices
Started by:
- 3
- February 11, 2018 at 12:00 am
-
Professional Referral Network
Started by:
- 4
- February 8, 2018 at 11:34 pm
-
Probiotics
Started by:
- 5
- February 7, 2018 at 3:43 pm
-
Monitoring for toxicty
Started by:
- 2
- February 5, 2018 at 2:48 am
-
New BRAF/MEK inhibitors coming to market
Copyright ©2022- - AIM with Immunotherapy. All rights reserved.